These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 19015010)
21. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS Int J Neuropsychopharmacol; 2009 Jul; 12(6):823-32. PubMed ID: 19154656 [TBL] [Abstract][Full Text] [Related]
22. Involvement of glutamatergic and GABAergic transmission in MK-801-increased gamma band oscillation power in rat cortical electroencephalograms. Hiyoshi T; Kambe D; Karasawa J; Chaki S Neuroscience; 2014 Nov; 280():262-74. PubMed ID: 25220900 [TBL] [Abstract][Full Text] [Related]
23. The effects of ketamine and risperidone on eye movement control in healthy volunteers. Schmechtig A; Lees J; Perkins A; Altavilla A; Craig KJ; Dawson GR; William Deakin JF; Dourish CT; Evans LH; Koychev I; Weaver K; Smallman R; Walters J; Wilkinson LS; Morris R; Williams SC; Ettinger U Transl Psychiatry; 2013 Dec; 3(12):e334. PubMed ID: 24326395 [TBL] [Abstract][Full Text] [Related]
24. Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. Chatterjee M; Ganguly S; Srivastava M; Palit G Behav Brain Res; 2011 Jan; 216(1):247-54. PubMed ID: 20699106 [TBL] [Abstract][Full Text] [Related]
25. (+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. Cilia J; Hatcher P; Reavill C; Jones DN J Psychopharmacol; 2007 May; 21(3):302-11. PubMed ID: 17591657 [TBL] [Abstract][Full Text] [Related]
26. Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice. Featherstone RE; Nagy LR; Hahn CG; Siegel SJ Drug Alcohol Depend; 2014 Jan; 134():123-127. PubMed ID: 24210161 [TBL] [Abstract][Full Text] [Related]
27. NMDA antagonist MK801 recreates auditory electrophysiology disruption present in autism and other neurodevelopmental disorders. Saunders JA; Gandal MJ; Roberts TP; Siegel SJ Behav Brain Res; 2012 Oct; 234(2):233-7. PubMed ID: 22771812 [TBL] [Abstract][Full Text] [Related]
28. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Duncan GE; Moy SS; Lieberman JA; Koller BH Pharmacol Biochem Behav; 2006 Nov; 85(3):481-91. PubMed ID: 17097724 [TBL] [Abstract][Full Text] [Related]
29. Complex receptor mediation of acute ketamine application on in vitro gamma oscillations in mouse prefrontal cortex: modeling gamma band oscillation abnormalities in schizophrenia. McNally JM; McCarley RW; McKenna JT; Yanagawa Y; Brown RE Neuroscience; 2011 Dec; 199():51-63. PubMed ID: 22027237 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Kittelberger K; Hur EE; Sazegar S; Keshavan V; Kocsis B Brain Struct Funct; 2012 Apr; 217(2):395-409. PubMed ID: 21979451 [TBL] [Abstract][Full Text] [Related]
32. Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Featherstone RE; Liang Y; Saunders JA; Tatard-Leitman VM; Ehrlichman RS; Siegel SJ Neurobiol Dis; 2012 Sep; 47(3):338-46. PubMed ID: 22627142 [TBL] [Abstract][Full Text] [Related]
33. Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression. Featherstone RE; M Tatard-Leitman V; Suh JD; Lin R; Lucki I; Siegel SJ Psychopharmacology (Berl); 2013 Jun; 227(4):639-49. PubMed ID: 23392353 [TBL] [Abstract][Full Text] [Related]
34. Ketamine-induced deficit of auditory gating in the hippocampus of rats is alleviated by medial septal inactivation and antipsychotic drugs. Ma J; Tai SK; Leung LS Psychopharmacology (Berl); 2009 Oct; 206(3):457-67. PubMed ID: 19655127 [TBL] [Abstract][Full Text] [Related]
36. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia. Moxon KA; Gerhardt GA; Adler LE Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485 [TBL] [Abstract][Full Text] [Related]
37. Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model. Haaf M; Leicht G; Curic S; Mulert C Curr Pharm Biotechnol; 2018; 19(4):293-307. PubMed ID: 29929462 [TBL] [Abstract][Full Text] [Related]
38. Glutamatergic modulation of auditory information processing in the human brain. Gunduz-Bruce H; Reinhart RM; Roach BJ; Gueorguieva R; Oliver S; D'Souza DC; Ford JM; Krystal JH; Mathalon DH Biol Psychiatry; 2012 Jun; 71(11):969-77. PubMed ID: 22036036 [TBL] [Abstract][Full Text] [Related]
39. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Hajós M; Hoffmann WE; Kocsis B Biol Psychiatry; 2008 Jun; 63(11):1075-83. PubMed ID: 18261715 [TBL] [Abstract][Full Text] [Related]